ESMO Congress 2023 Oct 20 - Oct 24, 2023 Poster title: GALLANT-1: GB1211 Galectin-3 (Gal-3) inhibitor plus atezolizumab (atz) for first line treatment in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) https://www.esmo.org
